As of Mar 22
| -0.18 / -6.64%|
The 3 analysts offering 12-month price forecasts for Vyne Therapeutics Inc have a median target of 72.00, with a high estimate of 90.00 and a low estimate of 28.00. The median estimate represents a +2,701.56% increase from the last price of 2.57.
The current consensus among 3 polled investment analysts is to Buy stock in Vyne Therapeutics Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.